BARDA contracted to develop burn treatment
The three-year contract is worth approximately $8.2 million and will allow the company to continue development of its biodegradable temporizing matrix (BTM) for burn injuries. The funding comes from the Biomedical Advanced Research and Development Authority.
Typically, a burn injury requires surgical intervention to fully repair damaged skin tissue and larger burn areas require the use of skin grafts from donors. With the BTM, the wounds can be covered and prevent contraction of the wounded tissue in order to better support victims prior to surgery.
Under this contract, the company will take part in early clinical studies to determine feasibility and will also take on nonclinical studies and manufacture necessary materials for study purposes. This contract also includes the possibility of a five-year extension worth up to an additional $26.3 million.
According to the announcement, this kind of product would be crucial for treatment during a mass casualty event in which multiple patients are needing similar supplies that could be scarce. The BTM would allow for medical professionals to treat victims efficiently.
Currently, there is one Food and Drug Administration-approved product for burn coverage and wound closure.